All In MedTech

Device Trial Radar · NCT04722250

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 1,103 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,103

Actual

Start

Apr 2, 2021

Primary completion

Nov 10, 2023

Study completion Dec 2027

Sponsor

Lead sponsor
Medtronic CardiovascularPublic (MDT)
Sponsor type
Industry
First posted
Jan 25, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to generate clinical evidence on valve safety and performance of self-expanding (SE) versus balloon-expandable (BE) transcatheter aortic valve replacement (TAVR) in subjects with a small aortic annulus and symptomatic severe native aortic stenosis. Additionally, a stress echocardiography sub-study will be conducted as part of the SMART Trial at select sites. The purpose of the sub-study is to evaluate performance of SE versus BE TAVR in subjects with a small aortic annulus and symptomatic severe native aortic stenosis after undergoing exercise stress echocardiographic testing.

Conditions

  • Symptomatic Aortic Stenosis
  • Aortic Valve Stenosis
  • Aortic Valve Replacement

Interventions

  • Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV SystemsDevice

    TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)

  • Edwards SAPIEN 3 or SAPIEN 3 Ultra THV SystemsDevice

    TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality, Disabling Stroke or Heart Failure RehospitalizationTime frame: 12 months
  2. Bioprosthetic Valve Dysfunction (BVD)Time frame: 12 months

Locations

92 sites in 13 countries. Site status is shown where the registry gives one.

  • Scripps Memorial Hospital

    La Jolla, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Sutter Health

    San Francisco, California

89 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.